Literature DB >> 18233951

Molecular mechanisms of prion pathogenesis.

Adriano Aguzzi1, Christina Sigurdson, Mathias Heikenwaelder.   

Abstract

Prion diseases are infectious neurodegenerative diseases occurring in humans and animals with an invariably lethal outcome. One fundamental mechanistic event in prion diseases is the aggregation of aberrantly folded prion protein into large amyloid plaques and fibrous structures associated with neurodegeneration. The cellular prion protein (PrPC) is absolutely required for disease development, and prion knockout mice are not susceptible to prion disease. Prions accumulate not only in the central nervous system but also in lymphoid organs, as shown for new variant and sporadic Creutzfeldt-Jakob patients and for some animals. To date it is largely accepted that prions consist primarily of PrPSc, a misfolded and aggregated beta-sheet-rich isoform of PrPC. However, PrPSc may or may not be completely congruent with the infectious moiety. Here, we discuss the molecular mechanisms leading to neurodegeneration, the role of the immune system in prion pathogenesis, and the existence of prion strains that appear to have different tropisms and biochemical characteristics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18233951     DOI: 10.1146/annurev.pathmechdis.3.121806.154326

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  155 in total

Review 1.  Protective effects and mechanisms of sirtuins in the nervous system.

Authors:  Feng Zhang; Suping Wang; Li Gan; Peter S Vosler; Yanqin Gao; Michael J Zigmond; Jun Chen
Journal:  Prog Neurobiol       Date:  2011-09-10       Impact factor: 11.685

2.  Analysis of single nucleotide polymorphisms of PRNP gene in twenty-four ethnic groups of India.

Authors:  Mainak Sengupta; Amrita Chakraborty; Kunal Ray
Journal:  J Genet       Date:  2010-08       Impact factor: 1.166

3.  Influence of pH on the human prion protein: insights into the early steps of misfolding.

Authors:  Marc W van der Kamp; Valerie Daggett
Journal:  Biophys J       Date:  2010-10-06       Impact factor: 4.033

4.  In vitro neutralization of prions with PrP(Sc)-specific antibodies.

Authors:  Ryan Taschuk; Jacques Van der Merwe; Kristen Marciniuk; Andrew Potter; Neil Cashman; Philip Griebel; Scott Napper
Journal:  Prion       Date:  2015       Impact factor: 3.931

Review 5.  Prions and the potential transmissibility of protein misfolding diseases.

Authors:  Allison Kraus; Bradley R Groveman; Byron Caughey
Journal:  Annu Rev Microbiol       Date:  2013-06-28       Impact factor: 15.500

Review 6.  Copper-dependent regulation of NMDA receptors by cellular prion protein: implications for neurodegenerative disorders.

Authors:  Peter K Stys; Haitao You; Gerald W Zamponi
Journal:  J Physiol       Date:  2012-02-06       Impact factor: 5.182

Review 7.  An emerging concept of prion infections as a form of transmissible cerebral amyloidosis.

Authors:  Omar Lupi; Marcius Achiame Peryassu
Journal:  Prion       Date:  2007 Oct-Dec       Impact factor: 3.931

Review 8.  Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions.

Authors:  Byron Caughey; Gerald S Baron; Bruce Chesebro; Martin Jeffrey
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

9.  Conformational Dynamics in the Core of Human Y145Stop Prion Protein Amyloid Probed by Relaxation Dispersion NMR.

Authors:  Matthew D Shannon; Theint Theint; Dwaipayan Mukhopadhyay; Krystyna Surewicz; Witold K Surewicz; Dominique Marion; Paul Schanda; Christopher P Jaroniec
Journal:  Chemphyschem       Date:  2018-11-07       Impact factor: 3.102

10.  PrP mRNA and protein expression in brain and PrP(c) in CSF in Creutzfeldt-Jakob disease MM1 and VV2.

Authors:  Franc Llorens; Belén Ansoleaga; Paula Garcia-Esparcia; Saima Zafar; Oriol Grau-Rivera; Irene López-González; Rosi Blanco; Margarita Carmona; Jordi Yagüe; Carlos Nos; José Antonio Del Río; Ellen Gelpí; Inga Zerr; Isidre Ferrer
Journal:  Prion       Date:  2013-09-18       Impact factor: 3.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.